A5089660949- Cancer, Hypoxia, and Metabolism
- Nanoplatforms for cancer theranostics
- MRI in cancer diagnosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Lanthanide and Transition Metal Complexes
- Cancer, Lipids, and Metabolism
- Ovarian cancer diagnosis and treatment
- Angiogenesis and VEGF in Cancer
- Cancer Genomics and Diagnostics
- Eicosanoids and Hypertension Pharmacology
- Cancer Research and Treatments
- DNA Repair Mechanisms
- Nanoparticle-Based Drug Delivery
- RNA modifications and cancer
- Bladder and Urothelial Cancer Treatments
- Single-cell and spatial transcriptomics
- Peptidase Inhibition and Analysis
- Biochemical and Molecular Research
- Microtubule and mitosis dynamics
- Nuclear Receptors and Signaling
- Pancreatic and Hepatic Oncology Research
- Liver physiology and pathology
- RNA Interference and Gene Delivery
- Chromatin Remodeling and Cancer
- Cancer-related gene regulation
University of Göttingen
2023-2024
Universitätsmedizin Göttingen
2023-2024
Walter Reed National Military Medical Center
2019-2020
Uniformed Services University of the Health Sciences
2019-2020
Inova Health System
2013-2020
The majority of patients diagnosed with advanced epithelial ovarian carcinoma (EOC) relapse resistant disease, and there are no biomarkers that possess clinical utility to identify or monitor these patients. This study aimed secreted proteins (‘secretome’) collected from human EOC cell lines differ in their inherent platinum sensitivity. Secreted conditioned medium cancer vary sensitivity cisplatin were digested trypsin analysed by liquid chromatography-tandem mass spectrometry for peptide...
<p>Supplementary Fig. 4</p>
<p>Supplementary Fig. 3</p>
<p>Supplementary Fig. 2</p>
<p>Supplementary Fig. 7</p>
<p>Supplementary Fig. 5</p>
<p>Supplementary Fig.1</p>
<p>Supplementary Fig. 6</p>
Most clinical diagnostic and genomic research setups focus almost exclusively on coding regions essential splice sites, thereby overlooking other non-coding variants. As a result, intronic variants that can promote mis-splicing events across range of diseases, including cancer, are yet to be systematically investigated. Such investigations would require both transcriptomic data, but there currently exist very few datasets satisfy these requirements. We address this by developing...
Abstract Treatment of patients with locally advanced rectal cancer (RC) is based on neoadjuvant chemoradiotherapy followed by surgery. In order to reduce the development therapy resistance, it necessary further improve previous treatment approaches. Recent in vivo experimental studies suggested that reduction tumor hypoxia vessel normalization (TVN), through inhibition glycolytic activator PFKFB3, could significantly response therapy. We have evaluated vitro and effects PFKFB3 inhibitor...
Abstract Most clinical diagnostic and genomic research setups focus almost exclusively on coding regions essential splice sites, thereby overlooking other non-coding variants. As a result, intronic variants that can promote mis-splicing events across range of diseases, including cancer, are yet to be systematically investigated. Such investigations would require both transcriptomic data, but there currently exist very few datasets satisfy these requirements. We address this by developing...
<p>3PO reduces colorectal cancer cell invasion and endothelial sprouting capabilities. <b>A,</b> Invasion assay performed with HCT-116, HT-29, SW-1463, SW-837 cells. Cells were plated in a Boyden multi-well chamber treated 10 µmol/L 3PO for period of 96 hours. Data are displayed as means SD, <i>n</i> = 3. <sup>∗∗</sup>, <i>P</i> < 0.01; <sup>∗∗∗∗</sup>, 0.0001; Student <i>t</i> test. <b>B,</b>...
<p>Supplementary Fig. 3</p>
<p><i>In vivo</i> 3PO administration in combination with radiotherapy induces TVN and alleviates hypoxia RC. <b>A,</b> Representative images of CD31<sup>+</sup>αSMA<sup>+</sup> co-stained sections PDX tumors upon treatment vehicle (comtrol), 3PO, RT, + RT. Scale bars, 100 μm. <b>B–D,</b> Quantification CD31<sup>+</sup> αSMA<sup>+</sup> area (%), vessel lumen size (µm<sup>2</sup>), tumor...
<p>Supplementary Fig. 3</p>
<p>Gene set enrichment analysis of 3PO-treated colon organoids. <b>A,</b> Representative pictures patient-derived tumor organoids treated with 30 µmol/L 3PO for 24 hours. Scale bars, 200 μm. <b>B,</b> Patient-derived organoid size quantification. Data are displayed as means ± SD. <sup>∗</sup>, <i>P</i> < 0.05; one-way ANOVA. <b>C,</b> GSEA gene sets derived from the GO Biological Process ontology. For plot (score curves),...
<p>Supplementary Fig. 5</p>
<p>Supplementary Fig. 5</p>
<p>Supplementary Fig. 6</p>
<p><i>In vivo</i> 3PO administration in combination with radiotherapy induces TVN and alleviates hypoxia RC. <b>A,</b> Representative images of CD31<sup>+</sup>αSMA<sup>+</sup> co-stained sections PDX tumors upon treatment vehicle (comtrol), 3PO, RT, + RT. Scale bars, 100 μm. <b>B–D,</b> Quantification CD31<sup>+</sup> αSMA<sup>+</sup> area (%), vessel lumen size (µm<sup>2</sup>), tumor...
<p>Supplementary Fig. 2</p>
<p>Supplementary Fig. 7</p>
<p>Supplementary Fig.1</p>